Transfusion-Ready Platelets for Patients
Reduced Risk of Bacterial Contamination and Sepsis
In fact, FDA has made clear through pending guidance that standard aerobic primary culture alone is insufficient to protect the platelet supply, and have called for new measures to minimize risk of bacterial contamination.1
Effective in reducing the risk of transfusion-transmitted infections (TTI),12 pathogen reduction for platelet components provides a solution to blood centers and hospital clients that ultimately benefits patients who need it most.
Not only does pathogen reduction comply with FDA’s pending guidance on addressing bacterial contamination,1 it reduces risk beyond bacteria with mitigation of TTI due to viruses and parasites, as well as TA-GVHD due to T-Cells.12
*Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.
Rx Only. For CONTRAINDICATIONS and WARNINGS, click here. See package insert for full prescribing information – available on the resource page. There is no pathogen inactivation process that has been shown to eliminate all pathogens. ©2019 Cerus Corporation. All Rights Reserved. INTERCEPT, INTERCEPT Blood System and CERUS are registered trademarks of Cerus Corporation. This site is intended for US audiences only. MKT-EN 00155 v8.0